Prevacus competitorsClear all

Prevacus's top competitors include Biogen, Otonomy, Ironwood Pharmaceuticals and Alimera Sciences.
Prevacus
Prevacus
Prevacus is a pharmaceutical company developing a treatment for concussions also known as mild traumatic brain injuries.
Biogen
Biogen
Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Alimera Sciences
Alimera Sciences
Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Founding Date
Founding Date
2012
Founding Date
1978
Founding Date
2008
Founding Date
N/A
Founding Date
2003
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Tallahassee, US HQ
Locations
Cambridge, US HQ
Vicente López, AR
Macquarie Park, AU
Wien, AT
Machelen, BE
São Paulo, BR
Mississauga, CA
see more
Locations
San Diego, US HQ
Locations
Cambridge, US HQ
Boston, US
Locations
Alpharetta, US HQ
Berlin, DE
Dublin 2, IE
Lisboa, PT
Hampshire, GB
Employees
Employees
5
Employees
7,4005% decrease
Employees
49
Employees
31738% decrease
Employees
1222% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
41.5 b
Valuation ($)
237.8 m
Valuation ($)
1.7 b
Valuation ($)
45.8 m
Twitter followers
Twitter followers
382
Twitter followers
36.3 k
Twitter followers
214
Twitter followers
3.7 k
Twitter followers
2.3 k
Number of tweets (last 30 days)
Number of tweets (last 30 days)
1
Number of tweets (last 30 days)
28
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
1
Average likes per tweet (last 30 days)
21.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
2
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
96.43%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
307662
Alexa Website Rank
254464
Alexa Website Rank
339305
Alexa Website Rank
313890
Alexa Website Rank
185996
Employee Rating
Employee Rating
N/A
Employee Rating
4.1
Employee Rating
4.3
Employee Rating
4.1
Employee Rating
3.8

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$14.4b (FY, 2019)
Revenue (est.)
$600k (FY, 2019)
Revenue (est.)
$428.4m (FY, 2019)
Revenue (est.)
$53.9m (FY, 2019)
Cost of goods
Cost of goods
N/A
Cost of goods
$2b (FY, 2019)
Cost of goods
$912k (FY, 2019)
Cost of goods
$23.9m (FY, 2019)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$12.4b (FY, 2019)
Gross profit
($312k) (FY, 2019)
Gross profit
$404.5m (FY, 2019)
Gross profit
N/A
Net income
Net income
N/A
Net income
$5.9b (FY, 2019)
Net income
($44.7m) (FY, 2019)
Net income
$21.5m (FY, 2019)
Net income
($10.4m) (FY, 2019)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
34 (FY, 2019)
Patents Issued
88 (FY, 2016)
Patents Issued
N/A
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
13 (Q3, 2020)
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
9 (Q3, 2020)
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
6 (Q3, 2020)
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 153.4m
Total funding raised
$ 609m
Total funding raised
$ 232.6m
For sources of this data, please see the company profile

View company profiles

Biogen
HQ
Cambridge, US
Employees
7,400↓ 5% decrease

Biogen is a biopharmaceutical company that discovers, develops, and delivers innovative therapies for people living with serious neurological and neurodegenerative diseases.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Ironwood Pharmaceuticals
HQ
Cambridge, US
Employees
317↓ 38% decrease

Ironwood Pharmaceuticals, an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.

View company
Alimera Sciences
HQ
Alpharetta, US
Employees
122↓ 2% decrease

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.

View company